CogState (CGS.AX) Akcija Kursas
CogState Kursas
Per pastaruosius 19 metus CogState pajamos augo 20,0 % kasmet ir pasiekė 53,09 mln. USD. Pelnas akcijai augo 8,5 % per metus per pastaruosius 16 metus. CogState grynoji marža 19,1 % yra išaugo palyginti su 16,0 % prieš kelerius metus. Esama kaina dividendo pajamingumas yra apie 1,19 %. Išmokų koeficientas yra apie 34 % pelno. CogState 12 mėn. konsensuso tikslinė kaina yra 2,15 USD, apie žemiau kursą 10,3 %. Iš 6 analitikų 5 rekomenduoja pirkti — bendras konsensusas yra Pirkti.
CogState akcijos kaina
CogState akcija ir akcijų analizė
Dažnai užduodami klausimai apie CogState akciją
CogState Ltd is a leading provider of cognitive testing services for clinical trials, academic research, and healthcare. The company's business model revolves around using their digital tools and technologies to measure and enhance cognitive function in patients. By collaborating with pharmaceutical companies, academic institutions, and healthcare organizations, CogState Ltd aims to improve patient outcomes and accelerate the development of new treatments. With their expertise and extensive database, CogState Ltd offers customized solutions and prognostic insights to address the cognitive challenges faced in various industries.
CogState Ltd is primarily active in the healthcare and pharmaceutical industries.
The main competitors of CogState Ltd in the market are Cambridge Cognition Holdings PLC, Neurotrack Technologies Inc., and CogniFit Ltd. These companies also specialize in cognitive assessment and provide similar solutions and services. However, CogState Ltd distinguishes itself through its innovative technologies and partnerships, including collaborations with leading pharmaceutical companies. With its strong focus on enhancing the understanding and measurement of cognitive function, CogState Ltd continues to remain competitive in the market and deliver valuable solutions to its clients.
CogState Ltd is a renowned company with a rich history and background. Founded in 1999, CogState specializes in cognitive testing and offers innovative solutions to improve brain health assessment. With its headquarters in Melbourne, Australia, the company has expanded its global presence, serving various sectors including pharmaceuticals, biotechnology, and academic research. CogState has developed cutting-edge technologies and software platforms to deliver accurate and efficient cognitive assessments, benefiting patients, researchers, and professionals worldwide. Known for its advanced cognitive testing methods and commitment to enhancing brain health, CogState Ltd has established itself as a trusted industry leader.
CogState Ltd has achieved several significant milestones in its history. One key achievement is the development and commercialization of its pioneering cognitive testing technology, known as the CogState Computerized Cognitive Assessment Tool (CCAT). This innovative tool is widely utilized in clinical trials and research studies worldwide, enabling precise and objective measurement of cognitive function. Additionally, CogState Ltd has successfully established strategic partnerships with leading pharmaceutical companies, academic institutions, and healthcare providers, facilitating the widespread adoption of its solutions. The company continues to thrive through ongoing research and development, further cementing its position as a global leader in cognitive assessment technology.
CogState Ltd is primarily present in Australia, the United States, and Europe.
CogState Ltd represents a set of core values and a corporate philosophy that drive its operations. The company is committed to innovation, delivering cutting-edge solutions in the fields of cognitive assessment and clinical trials. CogState prioritizes integrity, ensuring transparent and ethical practices in all aspects of its business. With a focus on collaboration, CogState fosters strong partnerships to drive mutual success. The company values dedication to excellence, constantly striving for improvement and delivering high-quality products and services. CogState fosters a customer-centric approach, prioritizing customer satisfaction and delivering tailored solutions. Overall, CogState Ltd embodies a commitment to innovation, integrity, collaboration, excellence, and customer-centricity in its corporate philosophy.
Analitikai šiuo metu nustato vidutinę CogState akcijos tikslinę kainą 2,15 USD (mediana: 2,15 USD), t. y. −10,3 % palyginti su paskutine kaina. Konsensusas pagrįstas 6 analitikų reitingais.
7 analitikai šiuo metu vertina CogState akciją: 6 rekomenduoja pirkti, 1 laikyti ir 0 parduoti. 2026 m. analitikai tikisi, kad CogState gaus 128,65 mln. USD pajamų ir 0,09 USD pelno akcijai.
Pagal dabartinį kursą CogState akcija kainuoja 2,14 EUR (2,40 USD).
CogState akcija (CGS.AX) kotiruojama 2 biržose, įskaitant: ASX (CGS.AX).
CogState Ltd is an innovative company specializing in the development and marketing of cognitive testing solutions. The company offers a wide range of products and services that can be used in the fields of pharmaceutical research, clinical diagnostics, and sports performance optimization. The three main business divisions of CogState Ltd include research and development of cognitive tests, clinical diagnostics and monitoring of patients with neurodegenerative disorders, and solutions for improving sports performance. The company's products are rooted in today's technology, as they are exclusively offered online. They allow for remote diagnosis and supervision of patients, saving time for therapists and improving diagnostic accuracy. The company's proprietary software platform enables researchers to effectively manage their studies and present study results in a concise format. CogState Ltd has a strategy in place to continue offering unique and expanding product offerings, allowing the company to remain a strong competitor in the industry.
tikėtina pelnas CogState yra 128,65 mln. USD. Šis skaičius grindžiamas dabartiniais finansiniais duomenimis ir atspindi įmonės verslo rezultatus.
tikėtina grynasis pelnas CogState yra 16,22 mln. USD. Grynasis pelnas atspindi įmonės pelningumą po visų išlaidų atimties.
Kainų ir nuomos santykis (KGV) CogState šiuo metu yra 25,75. KGV lygina dabartinę akcijos kainą su pelnu už akciją ir padeda investuotojams įvertinti CogState akcijos vertę.
Kainų ir pardavimų santykis (KUV) CogState šiuo metu yra 3,25. KUV lygina rinkos kapitalizaciją su metinėmis pajamomis ir yra CogState akcijos įvertinimo metrika.
Eulerpool kokybės balas CogState yra 6/10.
CogState ISIN yra AU000000CGS8. ISIN (International Securities Identification Number) yra pasaulinė unikali vertybinių popierių identifikacijos sistema.
CogState prekybos žymė yra CGS.AX. Ši biržos žymė naudojama CogState akcijoms prekiauti biržoje.
CogState akcija
CogState Pagrindiniai konkurentai
CogState Biržos simbolis
CogState FIGI
Visos CogState pagrindinės charakteristikos ir giluminė analizė
Mūsų akcijų analizė CogState akcijai apima svarbius finansinius rodiklius, tokius kaip apyvarta, pelnas, P/E santykis, P/S santykis, EBIT, taip pat informaciją apie dividendes. Be to, mes nagrinėjame aspektus, tokius kaip akcijos, rinkos kapitalizacija, skolos, nuosavas kapitalas ir įsipareigojimai CogState. Jei ieškote išsamesnės informacijos šiais klausimais, mūsų poskyriuose galite rasti išsamias analizes: